Harlan Waksal - 16 Feb 2022 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role: Executive Chair, Director
Signature: /s/ Jason Cavalier, Attorney-in-Fact for Harlan Waksal, M.D.
Issuer symbol: LYRA
Transactions as of: 16 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 18 Feb 2022, 16:09:45 UTC
Previous filing: 09 Nov 2021
Next filing: 13 Apr 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LYRA	Stock Option	Award	$0	+520,000		$0.000000	520,000	16 Feb 2022	Common Stock	520,000	$4.21	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On February 16, 2022, the Reporting Person was granted an option to purchase 520,000 shares of common stock. The option vests and becomes exercisable as to 173,333 shares underlying the option when the Issuer's market capitalization reaches $250,000,000; (ii) 173,333 shares underlying the option when the Issuer's market capitalization reaches $350,000,000; and (iii) 173,334 shares underlying the option when the Issuer's market capitalization reaches $500,000,000, all subject to the Reporting Person's continued service to the Issuer through each such date.

Content

On February 16, 2022, the Reporting Person was granted an option to purchase 520,000 shares of common stock. The option vests and becomes exercisable as to 173,333 shares underlying the option when the Issuer's market capitalization reaches $250,000,000; (ii) 173,333 shares underlying the option when the Issuer's market capitalization reaches $350,000,000; and (iii) 173,334 shares underlying the option when the Issuer's market capitalization reaches $500,000,000, all subject to the Reporting Person's continued service to the Issuer through each such date.